E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients hospitalized with acute heart failure (AHF), hypertension and mild to moderate renal impairment |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10007554 |
E.1.2 | Term | Cardiac failure |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The overall objectives of this study are to test the ability of relaxin to improve symptoms (dyspnea and signs of heart failure) and renal function in patients hospitalized with acute heart failure (AHF), hypertension and mild to moderate renal impairment; to evaluate the safety of relaxin in these patients; and to evaluate the ability of relaxin to reduce long term mortality/morbidity in these patients |
|
E.2.2 | Secondary objectives of the trial |
The secondary efficacy endpoints are: Proportion of patients with renal impairment defined as a ≥ 25% increase in serum creatinine from baseline to Day 5 Time from study drug initiation to death or rehospitalization for HF or renal dysfunction through Day 60 in the combined RELAX-AHF-1 and -2 studies |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Able to provide written informed consent 2. Male or female ≥ 18 years of age, with body weight <115 kg 3. Systolic blood pressure > 125 mmHg at the time of screening 4. Hospitalized for AHF. AHF is defined as including all of the following at screening: a. Dyspnea at rest or with minimal exertion b. Pulmonary congestion as evidenced by interstitial edema on chest radiograph c. BNP ≥ 350pg/mL or NT-pro-BNP ≥1400 pg/mL measured at any time between presentation (including the emergency department [ED]) and screening 5. Able to be randomized within 16 hours from presentation to the hospital, including the ED 6. Received IV furosemide of at least 40 mg (or equivalent) at any time between admission to emergency services (either ambulance or hospital, including the ED) and screening for the study 7. Impaired renal function defined as a creatinine clearance on admission between 30-75 mL/min, calculated using the simplified Modification of Diet in Renal Disease (sMDRD) equation |
|
E.4 | Principal exclusion criteria |
1. Pregnant or breast-feeding women (women of child bearing potential must have theresults of a negative pregnancy test recorded prior to study drug administration) 2. Administration of intravenous radiographic contrast agent within 72 hours prior to screening or acute contrast-induced nephropathy at the time of screening 3. Temperature >38C (oral or equivalent) or sepsis or active infection requiring IV antimicrobial treatment 4. Current (within 2 hours prior to screening) or planned (through the completion of study drug infusion) treatment with any IV therapies, including vasodilators (including nesiritide), positive inotropic agents and vasopressors, or mechanical support (intraaortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device), with the exception of IV nitrates at a dose of < 0.1 mg/kg/hr if the patient has a systolic BP > 150 mmHg at screening 5. Current or planned ultrafiltration, hemofiltration, or dialysis 6. Diabetic nephropathy with proteinuria +2 or greater by dipstick 7. Significant pulmonary disease (history of oral daily steroid dependency, history of dependency on bronchodilators or need for intubation in the past for acute exacerbation,or currently receiving IV steroids) 8. Significant stenotic valvular disease (severe aortic stenosis [AVA < 1.0 or peak gradient > 50 on prior or current echocardiogram], or severe mitral regurgitation, severe aortic regurgitation, or severe mitral stenosis) 9. Any organ transplant recipient, or patient currently listed for transplant or admitted for any transplantation 10. Major surgery within 30 days 11. Hematocrit < 25% or blood transfusion in the prior 14 days or active, life-threatening GI bleeding 12. Major neurologic event, including cerebrovascular events, in the prior 60 days 13. Clinical diagnosis of acute coronary syndrome within 45 days prior to screening(including the present admission) as determined by both clinical and enzymatic criteria 14. Troponin > 3 times the upper limit of normal between presentation and screening. 15. AHF due to significant arrhythmias (ventricular tachycardia, bradyarrhythmias with ventricular rate <45 beats per minute or any second or third degree AV block or atrial fibrillation/flutter with ventricular response of >120 beats per minute) 16. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (does not include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function) 17. Known hepatic impairment (as evidenced by total bilirubin > 3 mg/dL, albumin < 2.8 mg/dL, or increased ammonia levels if performed) 18. Non-cardiac pulmonary edema, including suspected sepsis 19. Administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days before screening or previous treatment with relaxin 20. Inability to follow instructions or comply with follow-up procedures |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients with marked or moderate improvement in subject-reported dyspnea score using the Likert 7-point scale at both 12 and 24 hours following the start of study drug infusion in the absence of worsening heart failure symptoms and signs between 3 and 24 hours following the start of study drug infusion. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
I pazienti saranno seguiti per un minimo di 60 giorni o per un massimo di 180 dall'amministrazione della prima dose del farmaco in studio |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |